Crossmark

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial

Crossref DOI link: https://doi.org/10.1186/s12885-022-09758-z

Published Online: 2022-06-18

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

van Heek, Lutz

Stuka, Colin

Kaul, Helen

Müller, Horst

Mettler, Jasmin

Hitz, Felicitas

Baues, Christian

Fuchs, Michael

Borchmann, Peter

Engert, Andreas

Dietlein, Markus

Voltin, Conrad-Amadeus

Kobe, Carsten
Funding

Funding for this research was provided by:

Universitätsklinikum Köln
License Information

Text and Data Mining valid from 2022-06-18

Version of Record valid from 2022-06-18
More Information

Article History

Received: 19 September 2021

Accepted: 10 June 2022

First Online: 18 June 2022

Declarations

:

: The study was ethically approved by the ethical review committee of the Medical Faculty of the University of Cologne. All patients gave their written consent to participate in the HD16 trial.

: Not applicable.

: All authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below